The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
ST Diepstraten, MA Anderson, PE Czabotar… - Nature Reviews …, 2022 - nature.com
Apoptosis is a form of programmed cell death that is regulated by the balance between
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …
Targeting apoptosis in cancer therapy
BA Carneiro, WS El-Deiry - Nature reviews Clinical oncology, 2020 - nature.com
For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …
of therapies promoting the effective elimination of cancer cells by apoptosis. This …
[HTML][HTML] Azacitidine and venetoclax in previously untreated acute myeloid leukemia
CD DiNardo, BA Jonas, V Pullarkat… - … England Journal of …, 2020 - Mass Medical Soc
Background Older patients with acute myeloid leukemia (AML) have a dismal prognosis,
even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had …
even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had …
Modes of regulated cell death in cancer
E Koren, Y Fuchs - Cancer discovery, 2021 - AACR
Cell suicide pathways, termed regulated cell death (RCD), play a critical role in organismal
development, homeostasis, and pathogenesis. Here, we provide an overview of key RCD …
development, homeostasis, and pathogenesis. Here, we provide an overview of key RCD …
[HTML][HTML] Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …
structures or functions that are difficult to interfere with using conventional drug design …
[HTML][HTML] Targeting MCL-1 in cancer: current status and perspectives
H Wang, M Guo, H Wei, Y Chen - Journal of hematology & oncology, 2021 - Springer
Abstract Myeloid leukemia 1 (MCL-1) is an antiapoptotic protein of the BCL-2 family that
prevents apoptosis by binding to the pro-apoptotic BCL-2 proteins. Overexpression of MCL …
prevents apoptosis by binding to the pro-apoptotic BCL-2 proteins. Overexpression of MCL …
Towards precision medicine for AML
With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
[HTML][HTML] Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer
Deregulation of the BCL-2 family interaction network ensures cancer resistance to apoptosis
and is a major challenge to current treatments. Cancer cells commonly evade apoptosis …
and is a major challenge to current treatments. Cancer cells commonly evade apoptosis …
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
R Singh, A Letai, K Sarosiek - Nature reviews Molecular cell biology, 2019 - nature.com
The loss of vital cells within healthy tissues contributes to the development, progression and
treatment outcomes of many human disorders, including neurological and infectious …
treatment outcomes of many human disorders, including neurological and infectious …
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
CD DiNardo, K Pratz, V Pullarkat… - Blood, The Journal …, 2019 - ashpublications.org
Older patients with acute myeloid leukemia (AML) respond poorly to standard induction
therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells …
therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells …